Pharmacoeconomic review report AbobotulinumtoxinA (Dysport therapeutic) (Ipsen Biopharmaceuticals Canada, Inc.)
AbobotulinumtoxinA (aboBoNTA) is a botulinum toxin that blocks nerve activity in the muscles, causing a temporary reduction in muscle activity. The recommended starting dosage of aboBoNTA for pediatric patients with lower-limb spasticity (LLS) is 10 U/kg to 15 U/kg for unilateral lower-limb injectio...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health
2017.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820271006719 |
| Sumario: | AbobotulinumtoxinA (aboBoNTA) is a botulinum toxin that blocks nerve activity in the muscles, causing a temporary reduction in muscle activity. The recommended starting dosage of aboBoNTA for pediatric patients with lower-limb spasticity (LLS) is 10 U/kg to 15 U/kg for unilateral lower-limb injections, or 20 U/kg to 30 U/kg for bilateral lower-limb injections per treatment session. Treatment can be administered to multiple sites of muscles within the lower limb. If the treatment effect from the first dose diminishes over time, patients can be re-treated after a period of at least 12 weeks. The manufacturer submitted a cost-utility analysis comparing aboBoNTA with onabotulinumtoxinA (onaBoNTA) in pediatric patients two years of age or older with unilateral or bilateral LLS. |
|---|---|
| Descripción Física: | 1 online resource (26 pages) |
